A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With PALBOCICLIB Compared With LETROZOLE Combined With PALBOCICLIB In Patients With estrogen receptor-positive, HER2-negative Locally Advanced Or Metastatic Breast Can

Condition: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Sponsor: Genetech_Roche

Phase: 3

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With PALBOCICLIB Compared With LETROZOLE Combined With PALBOCICLIB In Patients With estrogen receptor-positive, HER2-negative Locally Advanced Or Metastatic Breast Cancer